Rucaparib approved in US as monotherapy treatment for patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy

Approval for this 3rd indication for rucaparib is based on objective response rate and duration of response data from multi-centre, single arm TRITON2 trial. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory TRITON3 trial.


Biospace Inc.